Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds? [Yahoo! Finance]
MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at Mizuho to a "strong-buy" rating.
MannKind Co. (NASDAQ: MNKD) is now covered by analysts at Mizuho. They set an "outperform" rating and a $12.00 price target on the stock.
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.